Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0305 alone or with anticancer agents in relapsed or refractory multiple myeloma
2023-508590-89-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of AZD0305 in multiple myeloma (MM) (3 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
AZD0305
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-508590-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508590-89-00.